What is Vivoo?
Vivoo operates at the intersection of biotechnology and consumer wellness, providing a sophisticated platform for at-home health monitoring. By utilizing urine analysis, the company offers users immediate, personalized insights into critical health metrics, including hydration levels, vaginal pH, and fertility markers. This approach democratizes access to diagnostic data, moving away from traditional, clinical-heavy testing models toward a more accessible, user-centric paradigm. The company's core value proposition lies in its ability to translate complex biological data into actionable advice via a seamless mobile application, effectively empowering health-conscious individuals to manage their wellness journeys with scientific precision. As a key player in the digital health space, Vivoo is redefining how consumers interact with their own health data, fostering a proactive rather than reactive approach to personal care.
How much funding has Vivoo raised?
Vivoo has raised a total of $6M across 1 funding round:
Series A
$6M
Series A (2021): $6M with participation from 500 Global, Draper Associates, Global Ventures, ONCE Ventures, Revo Capital, and Halogen Ventures
Key Investors in Vivoo
500 Global
A prominent venture capital firm founded in 2010 that provides early-stage and growth-stage funding to innovative companies across the globe.
Draper Associates
A global venture capital firm with over 40 years of experience, specializing in backing transformative technologies and unconventional ideas that redefine industries.
Revo Capital
A venture capital firm focused on early-stage B2B and B2C technology ventures in Turkey and Eastern Europe, dedicated to nurturing the next generation of unicorns.
What's next for Vivoo?
Looking ahead, Vivoo is poised to leverage its recent capital infusion to drive product innovation and market penetration. The strategic focus will likely center on expanding the breadth of its diagnostic capabilities and enhancing the user experience within its digital interface. By scaling its R&D efforts, the company intends to broaden its reach, particularly among women managing fertility and general wellness, while simultaneously exploring new geographic markets. The backing from high-profile investors provides not only financial stability but also the strategic guidance necessary to navigate the complexities of the global health-tech landscape. As Vivoo continues to refine its algorithms and expand its diagnostic portfolio, it remains a company to watch for those tracking the evolution of personalized medicine and the broader consumerization of healthcare services.
See full Vivoo company page
